Oscare Medical was granted a patent in Europe

The European patent office has granted Oscare Medical a patent titled “Method and device for measuring density of a bone”, patent number 2252206. The patent concerns the osteoporosis detection method used by OsCare Sono®, which is based on measuring the propagation speed of sound along the surface (cortical) layer of a peripheral bone, travelling the same distance in opposite directions to eliminate adverse soft tissue effect. The term of patent protection is twenty years.

Oscare Medical already holds this patent in China and Japan.

The measurement method used by OsCare Sono® allows for an accurate and reliable measurement as the effect of the soft tissue is eliminated from the measurement, and as the real time display of the measured ultrasound waveforms allows for the operator to correctly position the sensor on top of the bone.

Oscare Medical signs distribution agreement with Remeda Allemann in Switzerland

Remeda Allemann + Partner GmbH has been providing healthcare technology solutions in Switzerland already since 1991. Remeda’s product portfolio includes Galileo vibration devices for rehabilitation and sports. The devices increase muscle strength, muscular performance and balance. The increase in muscular strength leads to bone growth in the medium term. Remeda also distributes Galileo’s pQCT (peripheral quantitative computed tomography) devices for the measurement of bone properties. The expertise in bone measurements and rehabilitation provides the personnel of Remeda excellent knowhow to start marketing the OsCare Sono® for osteoporosis screening in Switzerland. Remeda also provides surveillance, communication, alarm and GPS systems for hospitals, clinics and elderly homes.

The annual costs of hospitalizations for osteoporotic fractures in Switzerland are greater than those for myocardial infarction, stroke and breast cancer. The direct medical cost of hospitalization of patients with osteoporosis and related fractures was 357 million CHF in year 2000. Between 2000-2020, osteoporotic hip, vertebral and wrist fractures were predicted to rise by 33%, 27% and 19%, respectively.

The OsCare Sono® will enable easy and early detection of reduced bone strength and osteoporosis in clinics, doctor’s offices and pharmacies, helping the caregiver and patient to act early in order to prevent fractures.

For more information, please contact:

Managing Director Urs Allemann
REMEDA GMBH
Brahmsstrasse 18
8003 Zürich
T. +41 (0)44 491 30 27
Fax +41 (0)44 401 10 32
info@remeda.ch
www.remeda.ch

Visit us at Arab Health

Oscare Medical presents their unique solution for early osteoporosis assessment at Arab Health 2017 in Dubai from Monday January 30th to Thursday February 2nd. Welcome to visit us at the Finland Pavilion in hall S3 booth C60 to learn more about our easy and reliable bone strength measurement and to get an assessment of your own bone health!

ArabHealth_banneri_web

Visit us at Doctor 2017 convention in Helsinki 11.-13.1.2017

The yearly Doctor convention is Finland’s biggest healthcare convention and the most important training event of the year for doctors. Doctor 2017 will take place at the Messukeskus Expo and Convention Center in Helsinki, between January 11 and 13. The leading theme of Doctor 2017 is As a Doctor to the future.

Oscare Medical participates to the convention and showcases its unique, handheld device for assessing bone health and for identifying the individuals at risk for osteoporosis. The method is based on measuring the speed of low frequency ultrasound in the forearm radius bone. The results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), all important determinants of bone strength.

You are welcome to visit us in booth 3k58 to learn more about bone strength measurement with low frequency ultrasound and to get your own bone health assessed.

Contact information and other details for Doctor 2017 can be found at
http://laakaripaivat.fi/2017/in-english/
http://laakaripaivat.fi/2017/ (in Finnish)

Oscare Medical showcases unique handheld ultrasound device for assessment of osteoporosis at Medica 2016

Makes screening for osteoporosis simple, reliable and affordable

– Vantaa, Finland – Oscare Medical Oy announces that it will be demonstrating its handheld low frequency ultrasound device, the OsCare Sono® for osteoporosis assessment, at this year’s Medica at the Team Finland booth B5 in Hall 15. Medica, the world’s largest medical exhibition, will be held on 14th – 17th November in Düsseldorf, Germany.

Osteoporosis is estimated to affect 22 million women and 5.5 million men in Europe, with most of them unaware that they suffer from this silent disease until they suffer one or several low energy fractures. One out of three women and one out of five men 50 years old will experience osteoporotic fractures in their remaining lifetime.

The dual energy X-ray method (DXA) is the gold-standard for confirming a diagnosis of osteoporosis, but the expense, and limited availability, of DXA make it an impractical technique for screening people at an increased risk for osteoporosis. By assessing bone strength from the forearm radial bone using ultrasound, the OsCare Sono® allows for safe and inexpensive assessment of an individual’s osteoporosis risk. Because OsCare Sono® is easy to use and provides the measurement result in a matter of minutes, it is especially suitable for screening. Those individuals found to be at an increased risk for osteoporosis based on the OsCare Sono® measurement result, can be directed for further investigation with DXA, according to doctor’s judgement.

OsCare Sono® measurements have been shown to correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting that the device uniquely offers enhanced sensitivity to early osteoporotic changes.

About Oscare Sono®

The Oscare Sono® is a compact, handheld device designed for osteoporosis risk assessment in clinics and low-threshold locations, such as high street pharmacies. The device attaches via a USB connector to a standard PC. A measurement is taken from the forearm over a few minutes using harmless ultrasound. An individual’s measurement is compared to the normal value observed in healthy young women, and the final Oscare Sono® result is ready for counseling.

About Oscare Medical

Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp which also markets the hugely successful Icare® tonometer product family. The Oscare Sono® is CE-marked and is on sale in several European and Middle Eastern countries. Oscare Medical is rapidly expanding its distribution partner network. See: www.oscaremedical.com.

Contact:

Mervi Turunen

Sales & Marketing Manager

T: +358 40 732 4904

mervi.turunen@oscaremedical.fi

Visit us at Medica

Oscare Medical will be presenting their unique solution for early osteoporosis assessment at Medica 2016 in Düsseldorf from Monday 14th to Thursday 17th of November. Welcome to visit us in hall 15 at the Team Finland booth B5, to learn more about the easy and reliable bone strength measurement and to get an assessment of your own bone health!

Oscare Medical attends the EXPOPHARM pharmacy fair in München 12.-15.10.2016

Providing in-pharmacy health assessments is a growing trend in pharmacies. Many pharmacies already provide services such as blood pressure, blood glucose and cholesterol measurements as well as asthma management, to serve customers better and to grow their business.

Oscare Medical’s OsCare Sono® provides an easy and reliable way to assess bone health. Assessment of bone health and identification of individuals at risk for osteoporosis provides a valuable in-pharmacy service to everyone, but in particular for post-menopausal women and for other individuals at increased risk for osteoporosis, including smokers and those with diabetes or hyperthyroidism.

EXPOPHARM is the biggest pharmacy fair in Germany. Last year EXPOPHARM attracted almost 30 000 visitors, the majority of whom came from Germany.

Welcome to learn more about the OsCare Sono® bone health assessment and get your bone strength measured in hall C4 at Oscare Medical’s stand C-15!

New distributor for Oscare Medical in Portugal

VANTAA, Finland – Oscare Medical announces that i3o has been appointed as the distributor for the OsCare Sono® in Portugal. i3o has a solid background in the fields of optometry and ophthalmology, and is currently expanding its services to new markets. i3o’s organization includes highly qualified people with several years of experience in the field of medical technology. The policy of i3o is to be always near to the customer providing complete and prompt services.

Osteoporosis affects over 800.000 people in Portugal, and one in three over the age of 50 will suffer bone fractures within the next ten years. Fractures account for as many deaths in Portugal as breast cancer. The OsCare Sono® enables to recognize patients at a high risk for osteoporosis so they can be referred for further examinations and diagnostics. Early detection can help reduce the occurrence of low energy fractures, which can cause substantial pain and severe disability as well as costs to the society.

For more information, please contact:
i3o
Travessa da Presa Cachana, nº 25, Loja 4
3720265 Oliveira de Azeméis
Portugal
Tel./Fax: (+351) 256 690 270
E-mail: geral@i3o.pt
www.i3o.pt

First results of clinical study conducted in Lausanne University Hospital demonstrate good correlation between OsCare Sono® measurements and radius BMD

The first results of research conducted in Lausanne University Hospital with the OsCare Sono® were published as a poster at the International Society for Clinical Densitometry 22nd Annual Meeting, on June 1-4 2016 in Galway, Ireland. The study, “Assessment of a New Low Frequency Quantitative Ultrasound (QUS) Device for the Distal Radius”, demonstrated good correlation between the OsCare Sono® measurement results and radial BMD (bone mineral density), as measured by pDXA (peripheral DXA). The finding is in line with previous research findings, which have shown a good correlation to the radial BMD as measured by pQCT (peripheral quantitative computed tomography). The current research with the OsCare Sono® is being conducted in Lausanne University Hospital’s Center of Bone Diseases, Bone and Joint Department, by professor Didier Hans together with radiology technologists S. Soares, R. Pfaffen and A. Casmarrinha-Vieira as well as doctor M. Metzger and chief of department, doctor O. Lamy.

A total of 45 women on average 66 years of age were included in the study. The OsCare Sono® was used to measure the axial speed of low frequency ultrasound (VLF) at the radius. Each woman had three OsCare Sono® measurements in a row with repositioning. The correlation between the OsCare Sono® measurements (average of three measurements) and the radial BMD as measured by pDXA was good, r=0,82. The intra-operator RMS-CV (root mean square coefficient of variation) was 0,33 % for a skilled operator, and 0,41 % between three operators (one skilled and two beginners), indicating good repeatability for the measurement.

According to the researchers, the good correlation with radial bone mineral density may make OsCare Sono® suitable as a potential surrogate for peripheral DXA and for helping to find those individuals who are at a high risk for osteoporosis. Fracture prediction data, which is being collected as part of the research conducted in Lausanne University, will provide important additional information on the OsCare Sono® method.

Oscare Medical participates in bone health event in the Finnish parliament

On May the 26th Oscare Medical took part in a bone health event arranged by the Finnish Bone Association and the occupational health care department of the Finnish Parliament. The event attracted a lot of participants. Over a hundred members of the parliament, assistants and other personnel participated in bone strength measurements offered by Oscare Medical.

Bones are out of sight, so one does not easily come to think of their condition. Osteoporosis doesn’t usually give symptoms, but develops gradually during the years. 400 000 Finns have osteoporosis, and 30 000 to 40 000 osteoporotic fractures occur each year. One in three women and one in five men over 50 years of age suffer from osteoporotic fractures.

Osteoporosis is diagnosed with Dual-energy X-ray (DXA). DXA devices are large and expensive, and the measurement is not always easily accessible. The OsCare Sono® uses ultrasound to measure bone strength conveniently on the forearm. Combining the measurement result with other risk factors, it is possible to evaluate osteoporosis risk and whether a person should be sent for further examination. 95 % of patients diagnosed with osteoporosis based on DXA will receive an OsCare Sono® result indicating increased risk for osteoporosis. OsCare Sono® saves expenses, when only patients truly in need are sent for further examination. Using the OsCare Sono® can prevent human suffering and expenses caused by fractures. The yearly costs for one hip fracture can be up to 50 000 euros.